Trial · Interventional
CompletedPhase 1Registry dataALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
Overview
- Status
- Completed
- Phase
- Phase 1
- Enrollment
- 100 participants (actual)
- Sponsor
- Altimmune, Inc. · Industry
- Design
- Randomized · Double masking
- Countries
1 country
Australia
- Start
- 10 Nov 2020
- Primary completion
- 29 Oct 2021
- Completion
- 29 Oct 2021
- First posted
- 23 Sept 2020
- Last update posted
- 24 Jun 2025
- Conditions
- Obesity · Nonalcoholic Steatohepatitis
Timeline
1 trial · 1 completed
- Completed
- Ongoing
- Not yet recruiting
- Stopped
- Estimated dates (est.)
- Results posted
- Ph 1
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
NCT0456124510 Nov 2020 to 29 Oct 2021
Registry summary
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
This study was a FIH, Phase 1, randomized, double-blind, placebo-controlled, 2-part single-ascending dose (SAD) and multiple-ascending dose (MAD) study of ALT-801 (pemvidutide) in healthy overweight and obese subjects. The purpose of the study was to assess the safety and tolerability in healthy overweight and obese volunteers administered single or multiple repeated doses of ALT-801 (pemvidutide).
Interventions
- ALT-801Drug
- PlaceboOther
Arms4
Experimental
ALT-801 (Part 1)
Single ascending dose (SAD) cohorts of ALT-801
Placebo comparator
Placebo (Part 1)
Single dose of placebo
Experimental
ALT-801 (Part 2)
Multiple ascending dose (MAD) cohorts of ALT-801 administered once weekly for 12 weeks
Placebo comparator
Placebo (Part 2)
Placebo administered once weekly for 12 weeks
Primary outcomes5
Outcomes the sponsor listed as primary.
The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)
Time frame · Part 1 SAD Cohorts: up to Day 26; Part 2 MAD Cohorts: up to Day 42
Pharmacokinetic (PK): Maximum observed concentration (Cmax) of ALT-801
Time frame · Baseline, Day 26
Pharmacokinetic (PK): Area Under the Concentration (AUC) vs Time Curve of ALT-801
Time frame · Baseline to Day 26
Change in body weight
Time frame · Baseline to Week 6
Pharmacodynamic (PD): Change from baseline in magnetic resonance derived proton density fat fraction (MRI-PDFF)
Time frame · Baseline to Week 6
Posted results
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
No results are posted for this trial.
Completed trials do not always post results.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies0
Studies that cite this trial.
No study cites this trial.
Eligibility
Who could join, as posted.
- Sex
- All
- Age
- from 18 Years up to 60 Years
- Healthy volunteers
- Accepted
Inclusion and exclusion criteria, as posted
PepBank is a research reference. Talk to a doctor before you use any peptide.